UNSPSC 51112014: Erlotinib hydrochloride

This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C22H23N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DA87705X9K, chemically known as 4-quinazolinamine, n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride but more generally known as erlotinib hydrochloride, which bears US NIH Compound Identifier 176871.

UNSPSC 51112014 Erlotinib hydrochloride, a Commodity code, covers the supply of this specific oncology pharmaceutical to state and local government healthcare facilities. Recent state and local procurement under this code involves multi-source generic and branded pharmaceutical supply through cooperative purchasing vehicles. State and local health agencies, including corrections departments, public hospitals, and clinics, buy erlotinib and related oncology medications through these cooperative frameworks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant issuing vehicle; MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products covers erlotinib among a broader portfolio of therapeutics supplied to participating state and local facilities across multiple states including Oregon. Vendors must be FDA-compliant manufacturers holding current Good Manufacturing Practices (cGMP) certification and DSCSA compliance, maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), and offer flexible pricing structures such as flat price, net price formats, or WAC-minus models.

MMCAP's RFP, posted January 20, 2026 with proposals due March 26, 2026, represents the primary recent activity under this code. The cooperative purchasing model distributes pharmaceuticals across multiple states, with awarded vendors effective July 1, 2026 for an initial two-year term with optional extensions. Evaluation weights 75 percent to price competitiveness, 10 percent to fixed pricing for the contract term, and the remainder to administrative compliance, EDI capability, and the vendor's agreement to a 3 percent administrative fee. Vendors must carry professional liability insurance of $2,000,000 and commercial general liability of $5,000,000 per occurrence. The RFP does not identify specific budget ranges or set-aside designations in available documentation. Performance is measured against penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials, indicating a performance-driven contract structure common to state pharmaceutical supply agreements.